AB0420 UNINTENTIONAL MONOTHERAPY IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING TOFACITINIB AND DRUG SURVIVAL RATE OF TOFACITINIB

Background Combination of MTX with a bDMARDs or tsDMARDs is considered the most effective treatment regimen currently available for patients RA who have failed to respond conventional DMARDs. However, approximately 30% receive as monotherapy in daily clinical practice. Studies literature do not assess unintentional general. it thought that some may switch unintentionally. In other words, are prescribed combination therapy without informing their physicians. Objectives To determine rate rheumatoid arthritis (RA) receiving tofacitinib and evaluate survival rate. Methods This national, multicentre, retrospective study included patients’ data from TURKBIO Registry. Data on demographics, characteristics, disease duration activity, comorbidities, were analysed. Results 231 (84.8% female, median age, 56 years) included; 153 initially continued therapies; 31 but switched own will (unintentional monotherapy); 21 therapy; 26 therapies. The groups did differ regarding remission assessed by DAS28-CRP (60.5% 70%, respectively, p=0.328). comorbidities at time retrieval was significantly higher group compared (83.3% vs. 60.3%, p=0.031). Presence significant factor affecting switching (p=0.039, Odds ratio: 3.29, 95% CI: 1.06-10.18). Drug rates differ. drug 27+ months 1-year 4-year 89.6% 60.2%, group. Conclusion Although 13.4% population started unintentionally, different. Comorbidity an important transition monotherapy. sponsored Pfizer. Figure 1. Disclosure Interests Nevsun Inanc: None declared, Kerem Abacar: mehmet akif ozturk: Abdurrahman Tufan: Hazan Karadeniz: İsmail Sari: gercek can: Yesim Erez: yavuz Pehlivan: Ediz Dalkiliç: Tuğba Ocak: Ayse Cefle: Ayten Yazici Grant/research support from: has received project grant Roche Pharmaceuticals, Turkey., Senel: Servet Akar: Elif Durak Ediboglu: Süleyman Serdar Koca: Rabia Piskin Sagir: Sema Yilmaz: Semral Gulcemal: Özgül Soysal Gündüz: Canberk Sami Başibüyük Employee of: employee Pfizer Istanbul, Alkan shareholder Inc., Teoman Yusuf Cesur Fatos Onen: declared